CONFIDENTIAL PROVISIONS MARKED PATENT LICENSE AGREEMENT between PROTEIN DESIGN LABS, INC. and MEDIMMUNE, INC.Patent License Agreement • March 2nd, 2009 • PDL Biopharma, Inc. • Biological products, (no disgnostic substances) • California
This Agreement (“Agreement”), effective as of July 17, 1997 (“Effective Date”), is made by and between PROTEIN DESIGN LABS, INC., a Delaware corporation having offices at 2375 Garcia Avenue, Mountain View, CA 94043, USA (hereinafter “PDL”) and MEDIMMUNE, INC., a Delaware corporation, having offices at 35 West Watkins Mill Road, Gaithersburg, MD 20878 (hereinafter “MEDIMMUNE”).
CONFIDENTIAL PROVISIONS MARKED AMENDMENT NO. 2 TO THE PATENT LICENSING MASTER AGREEMENTPatent Licensing Master Agreement • March 2nd, 2009 • PDL Biopharma, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 2 to the Patent Licensing Master Agreement (“Amendment”) is entered into as of December 18, 2003 by and between Genentech, Inc. (“GNE”), a Delaware corporation having offices at 1 DNA Way, South San Francisco, California 94080 and Protein Design Labs, Inc. (“PDL”), a Delaware corporation having offices at 34801 Campus Drive, Fremont, California 94555 (collectively, the “Parties”) and amends that certain Patent Licensing Master Agreement dated September 25, 1998 (including the form PDL License Agreement attached thereto as Exhibit C), as amended by Amendment No. 1 to the Patent Licensing Master Agreement dated September 18, 2003 (collectively the “PLMA”). Except as expressly provided herein, capitalized terms shall have the meanings set forth in the PLMA and references to Sections, Exhibits and Articles shall be deemed references to the PLMA.
CONFIDENTIAL PROVISIONS MARKED PATENT LICENSE AGREEMENT between PROTEIN DESIGN LABS, INC. and ELAN INTERNATIONAL SERVICES LTD.Patent License Agreement • March 2nd, 2009 • PDL Biopharma, Inc. • Biological products, (no disgnostic substances) • California
This Agreement (“Agreement”), effective as of April 24, 1998 (“Effective Date”), is made by and between Protein Design Labs, Inc., a Delaware corporation having offices at 2375 Garcia Avenue, Mountain View, CA 94043 (hereinafter “PDL”) and Elan International Services Ltd., a Bermuda corporation and wholly-owned subsidiary of Elan Corporation plc, having offices at 102 St. James Court, Flatts, Smiths FL04, Bermuda (hereinafter “ELAN”).
AMENDMENT NO. 1 TO SEPARATION AND DISTRIBUTION AGREEMENTSeparation and Distribution Agreement • March 2nd, 2009 • PDL Biopharma, Inc. • Biological products, (no disgnostic substances) • Delaware
This Amendment No. 1 to Separation and Distribution Agreement is being entered into as of January 20, 2009 (this “Amendment”) by and between PDL BioPharma, Inc., a Delaware corporation (“PDL”), and Facet Biotech Corporation, a Delaware corporation (“Facet”) (each a “Party” and collectively, the “Parties”).
